Menu Search
Equities

Halozyme Therapeutics Inc

RV7:DUS

Halozyme Therapeutics Inc

Actions
  • Price (EUR)40.35
  • Today's Change0.07 / 0.17%
  • Shares traded20.00
  • 1 Year change+29.00%
  • Beta--
Data delayed at least 15 minutes, as of May 15 2024 07:11 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on reducing treatment burden for patients. It also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with several pharmaceutical companies. It markets and sells Hylenex recombinant, which is a formulation of rHuPH20. It markets and sells its proprietary product XYOSTED for SC administration of testosterone replacement therapy (TRT) in adult males.

  • Revenue in USD (TTM)862.99m
  • Net income in USD318.80m
  • Incorporated2007
  • Employees373.00
  • Location
    Halozyme Therapeutics Inc12390 EL CAMINO REALSAN DIEGO 92130United StatesUSA
  • Phone+1 (858) 794-8889
  • Fax+1 (302) 655-5049
  • Websitehttps://www.halozyme.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.